Eligibility Cannot be Raised in IPR Appeal

Neptune Generics v. Eli Lilly¬†(Fed. Cir. 2019) Mylan Labs v. Eli Lilly (Fed. Cir. 2019) This appeal combines twelve different inter partes review (IPR) proceedings. In each case, the PTAB Board sided with the patentee — holding that the claims of Lilly’s U.S. Patent 7,772,209 were not proven invalid.¬† On appeal, the Federal Circuit has … Continue reading Eligibility Cannot be Raised in IPR Appeal